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Abstract
We present a propensity-matched analysis of patients undergoing placement of dehy-
drated human amnion/chorion membrane (dHACM) around the neurovascular bundle
(NVB) during nerve-sparing (NS) robot-assisted laparoscopic prostatectomy (RARP). From
March 2013 to July 2014, 58 patients who were preoperatively potent (Sexual Health
Inventory for Men [SHIM] score >19) and continent (no pads) underwent full NS RARP.
Postoperative outcomes were analyzed between propensity-matched graft and no-graft
groups, including time to return to continence, potency, and biochemical recurrence.
dHACM use was not associated with increased operative time or blood loss or negative
oncologic outcomes (p > 0.500). Continence at 8 wk returned in 81.0% of the dHACM
group and 74.1% of the no-dHACM group (p = 0.373). Mean time to continence was
enhanced in group 1 patients (1.21 mo) versus (1.83 mo; p = 0.033). Potency at 8 wk
returned in 65.5% of the dHACM patients and 51.7% of the no-dHACM group (p = 0.132).
Mean time to potencywas enhanced in group1, (1.34mo), compared to group 2 (3.39mo;
p = 0.007).Graftplacementenhancedmeantime tocontinenceandpotency.Postoperative
SHIM scores were higher in the dHACM group at maximal follow-up (mean score 16.2 vs
9.1). dHACM allograft use appears to hasten the early return of continence and potency in
patients following RARP.
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E-mail address: vipul.patel.md@ﬂhosp.org (V.R. Patel).Over the last two decades there has been improvement in
our understanding of prostatic anatomy and the surgical
technique of radical prostatectomy. Robot-assisted radical
prostatectomy (RARP) has brought about advantages such
as enhanced 10 magnification, three-dimensional vision,
and the dexterity ofminiaturized instrumentation.However,
even for patientswithwell-preservedneurovascular bundles
(NVBs) there remains a convalescent period characterizedhttp://dx.doi.org/10.1016/j.eururo.2015.01.012
0302-2838/# 2015 European Association of Urology. Published by Elsevierby incontinence and impotence [1]. This delay is probably
due to an inflammatory response caused by traction injury to
the NVB [2].
Physical traction on the NVB can be minimized by the
surgeon but cannot be eliminated duringmobilization of the
prostate [3]. Tewari et al [3] used a traction monitor to
evaluate the aspects of RARP inflicting the greatestmechani-
cal force and showed that reduced NVB traction diminishesB.V. All rights reserved.
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hypothermia via a rectally placed cooling balloon. The group
demonstrated improvements in the return of urinary
continence, but not early sexual function. We have been
awaiting the next step in innovation that transcends the
technical aspectofnerve-sparing (NS)bybiologicallyaltering
the prostaticNVBneuropraxia induced by surgical dissection
[3]. Clinical use of growth factors and anti-inflammatory
substances for prostatic NVB regeneration is novel, and
dehydrated human amnion/chorion membrane (dHACM)
is a source of implantable neurotrophic factors and cytokines
[5,6]. The aim of our feasibility study was to ascertain if any
functional benefit could be measured after placement of
dHACM around the NVB following full NS RARP.
Full institutional board approval was granted for this
study. Patients were included from the period March
2013 to July 2014 at our institution. All RARP procedures[(Fig._1)TD$FIG]
Fig. 1 – Cumulative index curves showing (A) time to continence and (B) time
nonAmnioFix group, 1.83 mo (p = 0.033). Time to reach potency: AmnioFix growere performed by a single surgeon using the transper-
itoneal six-port technique with a Da Vinci surgical system
(Intuitive Surgical, Sunnyvale, CA, USA). Bilateral, retro-
grade, athermal NS RARP was performed in each patient,
with bladder neck reconstruction, an anterior suspension
stitch, and posterior reconstruction (Rocco stitch). There
were 58 patients in this series, who were preoperatively
continent (American Urological Association Symptom Score
<10) and potent (Sexual Health Inventory for Men [SHIM]
score >19) and underwent bilateral dHACM placement
(AmnioFix; MiMedx Group, Marietta, GA, USA) at a cost of
$900 per patient (Supplementary Fig. 1). The dHACM
allograft was cut into two longitudinal pieces and placed
over each NVB as a nerve wrap. The wrap was placed
circumferentially around the NVB after extirpative RARP,
post anastomosis. The dHACMstudy cohort (group 1; n = 58)
was computer-matched with a similar group of patientsto potency. Time to reach continence: AmnioFix group, 1.21 mo;
up, 1.34 mo; nonAmnioFix group, 3.39 mo (p = 0.007).
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multivariate design to create homogeneous groups.
Follow-up information was obtained through compre-
hensive questionnaires and clinic or telephone interviews.
Postoperative continence was defined as use of no pads per
day. Potency was reported by patients as the ability to
achieve and maintain an erection with or without a
phosphodiesterase type 5 inhibitor. A description of the
statistical analyses performed is provided in the Supple-
mentary methods. There were no significant preoperative
differences between the groups (Supplementary Table 1).
Intraoperative parameters were comparable between the
groups (Supplementary Table 2), with no postoperative
morbidity in either group (Supplementary Table 3).
The minimum 8-wk follow-up was complete for all
patients in both groups, with an average follow-up of 4 mo.
Continence at 8 wks returned in 81.0% of patients in group
1 and 74.1% of patients in group 2 (p = 0.373). The mean
time to continence was shorter in group 1 (1.21 mo) than in
group 2 (1.83 mo; p = 0.033, Fig. 1A). Potency at 8 wk
returned in 65.5% of group 1 patients and 51.7% of group
2 patients. The mean time to potency was significantly
shorter in group 1 (1.34 mo) than in group 2 (3.39 mo;
p = 0.007, Fig. 1B). SHIM scores were also higher for group
1 than for group 2 (mean score 16.2 vs 9.1).
We evaluated all patients at their first postoperative
visit at 8 wk. Our results indicate that dHACM placement
facilitates early return to continence and potency. The
mean times to potency and continence were significantly
shorter in the allograft group. dHACM facilitates wound
healing and has been used to treat burns, corneal injuries,
chronic venous ulcers, and chronic wounds [7]. Neuro-
trophic factors present in dHACM promote nerve cell
survival and maintain target organ function by facilitating
axon regeneration [8]. A number of recent experimental
studies using neurotrophic growth factors and dHACM
have provided encouraging data regarding the potential to
rehabilitate nerves after injury (Supplementary refer-
ences). The bilayered amnion and chorion membrane graft
we used has nonviable cells and an array of growth factors
(Supplementary Fig. 1).
Our data are encouraging for the study of anti-
inflammatory agents at the site of the prostatic NVB.
However, our study has several limitations; it is an
observational study with retrospective data collection
and is subject to patient recall bias. The lack of prospective
randomization is compensated by our large patient pool
available for propensity matching, and our optimal
matching algorithm ensured there were no significant
preoperative differences between the comparison groups
(Supplementary Table 1). Long-term oncologic results are
being recorded, and longer follow-up is required to evaluate
future outcomes for our cohort.
Following RARP, the degree of NVB preservation is
correlated to improved recovery of urinary continence and
potency [9], suggesting that preservation of neural tissue is
associated with enhanced functional outcomes, while the
NSmode (retrograde vs antegrade) has no impact onmargin
status [10]. In this study, dHACM accelerated the return ofcontinence and potency in patients following NS RARP, with
no adverse effects (Supplementary Table 4). An adequately
powered, prospective randomized trial and cost-benefit
analysis of dHACM around the prostatic NVB are now under
way to further ascertain the treatment effect of this new
approach. In conclusion, our short-term results are encour-
aging for patients undergoing full NS RARP and dHACM
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